Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Next Previous
Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications COVID 2019 infections; Respiratory insufficiency
  • Focus Proof of concept; Therapeutic Use
  • Sponsors CytoDyn

Most Recent Events

  • 02 Aug 2021 Primary endpoint (Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)) has not been met, according to a CytoDyn media release.
  • 23 Sep 2020 According to a CytoDyn media release, this study has been selected for an oral presentation at the upcoming Special isirv-Antiviral Group Conference on Therapeutics for COVID-19.The Conference is sponsored by the International Society for Influenza and other Respiratory Virus Diseases, an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus disease.
  • 10 Sep 2020 According to a CytoDyn media release, the company will host an investment community conference call on Wednesday, September 16, 2020 to provide updates regarding the U.S. Food and Drug Administration (FDA) emergency IND (eIND) program.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top